E,E,E-1-(4-Arylamino-4-oxo-2-butenoyl)-3,5-bis(arylidene)-4-piperidones

A topographical study of some novel potent cytotoxins

Amitabh Jha, Chandrani Mukherjee, Ashok K. Prasad, Virinder S. Parmar, Erik De Clercq, Jan Balzarini, James P. Stables, Elias Kurian Manavathu, Anuraag Shrivastav, Rajendra K. Sharma, Kurt H. Nienaber, Gordon A. Zello, Jonathan R. Dimmock

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

A series of E,E,E-3,5-bis(arylidene)-1-(4-arylamino-4-oxo-2-butenoyl)-4-piperidones 4 (phenylidene) and 5 (4-nitrophenylidene) were prepared in order to explore the structural features of the N-acyl group which affects the cytotoxic potency. Evaluation toward human Molt 4/C8 and CEM T-lymphocytes revealed that many of the IC50 figures were submicromolar and lower than melphalan. Marked inhibitory potencies toward murine leukemia L1210 cells were also noted. When evaluated against a panel of human tumor cell lines, three representative compounds in series 4 displayed selective toxicity to leukemia and colon cancer cell lines and were significantly more potent than the reference drug melphalan. Molecular modeling of representative compounds in both series 4 and the analogs, in which the configuration of the olefinic double bond was changed from E to Z (series 3), revealed that the torsion angles of the arylidene aryl rings and locations of the terminal arylaminocarbonyl groups may have contributed to the greater cytotoxic properties displayed in 3. Compounds 4c (3,4-dichlorophenylamino), d (4-methylphenylamino) and 5c (3,4-dichlorophenylamino), d (4-methylphenylamino) inhibited the activity of human N-myristoyltransferase by approximately 50% at concentrations of 50-100 μM. The compounds in series 4 and 5 were well tolerated in a short-term toxicity study in mice.

Original languageEnglish (US)
Pages (from-to)5854-5865
Number of pages12
JournalBioorganic and Medicinal Chemistry
Volume15
Issue number17
DOIs
StatePublished - Sep 1 2007

Fingerprint

Piperidones
Melphalan
Cytotoxins
Toxicity
Cells
Leukemia L1210
Molecular modeling
T-cells
Tumor Cell Line
Human Activities
Torsional stress
Colonic Neoplasms
Inhibitory Concentration 50
Tumors
Leukemia
T-Lymphocytes
Cell Line
Pharmaceutical Preparations

Keywords

  • 3,5-Bis(arylidene)-4-piperidones
  • Cytostatic activity
  • Human N-myristoyltransferase
  • Molecular modeling
  • Murine toxicity

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Jha, A., Mukherjee, C., Prasad, A. K., Parmar, V. S., Clercq, E. D., Balzarini, J., ... Dimmock, J. R. (2007). E,E,E-1-(4-Arylamino-4-oxo-2-butenoyl)-3,5-bis(arylidene)-4-piperidones: A topographical study of some novel potent cytotoxins. Bioorganic and Medicinal Chemistry, 15(17), 5854-5865. https://doi.org/10.1016/j.bmc.2007.05.065

E,E,E-1-(4-Arylamino-4-oxo-2-butenoyl)-3,5-bis(arylidene)-4-piperidones : A topographical study of some novel potent cytotoxins. / Jha, Amitabh; Mukherjee, Chandrani; Prasad, Ashok K.; Parmar, Virinder S.; Clercq, Erik De; Balzarini, Jan; Stables, James P.; Manavathu, Elias Kurian; Shrivastav, Anuraag; Sharma, Rajendra K.; Nienaber, Kurt H.; Zello, Gordon A.; Dimmock, Jonathan R.

In: Bioorganic and Medicinal Chemistry, Vol. 15, No. 17, 01.09.2007, p. 5854-5865.

Research output: Contribution to journalArticle

Jha, A, Mukherjee, C, Prasad, AK, Parmar, VS, Clercq, ED, Balzarini, J, Stables, JP, Manavathu, EK, Shrivastav, A, Sharma, RK, Nienaber, KH, Zello, GA & Dimmock, JR 2007, 'E,E,E-1-(4-Arylamino-4-oxo-2-butenoyl)-3,5-bis(arylidene)-4-piperidones: A topographical study of some novel potent cytotoxins', Bioorganic and Medicinal Chemistry, vol. 15, no. 17, pp. 5854-5865. https://doi.org/10.1016/j.bmc.2007.05.065
Jha, Amitabh ; Mukherjee, Chandrani ; Prasad, Ashok K. ; Parmar, Virinder S. ; Clercq, Erik De ; Balzarini, Jan ; Stables, James P. ; Manavathu, Elias Kurian ; Shrivastav, Anuraag ; Sharma, Rajendra K. ; Nienaber, Kurt H. ; Zello, Gordon A. ; Dimmock, Jonathan R. / E,E,E-1-(4-Arylamino-4-oxo-2-butenoyl)-3,5-bis(arylidene)-4-piperidones : A topographical study of some novel potent cytotoxins. In: Bioorganic and Medicinal Chemistry. 2007 ; Vol. 15, No. 17. pp. 5854-5865.
@article{8a4b9b368b7345afb929130883a1ea75,
title = "E,E,E-1-(4-Arylamino-4-oxo-2-butenoyl)-3,5-bis(arylidene)-4-piperidones: A topographical study of some novel potent cytotoxins",
abstract = "A series of E,E,E-3,5-bis(arylidene)-1-(4-arylamino-4-oxo-2-butenoyl)-4-piperidones 4 (phenylidene) and 5 (4-nitrophenylidene) were prepared in order to explore the structural features of the N-acyl group which affects the cytotoxic potency. Evaluation toward human Molt 4/C8 and CEM T-lymphocytes revealed that many of the IC50 figures were submicromolar and lower than melphalan. Marked inhibitory potencies toward murine leukemia L1210 cells were also noted. When evaluated against a panel of human tumor cell lines, three representative compounds in series 4 displayed selective toxicity to leukemia and colon cancer cell lines and were significantly more potent than the reference drug melphalan. Molecular modeling of representative compounds in both series 4 and the analogs, in which the configuration of the olefinic double bond was changed from E to Z (series 3), revealed that the torsion angles of the arylidene aryl rings and locations of the terminal arylaminocarbonyl groups may have contributed to the greater cytotoxic properties displayed in 3. Compounds 4c (3,4-dichlorophenylamino), d (4-methylphenylamino) and 5c (3,4-dichlorophenylamino), d (4-methylphenylamino) inhibited the activity of human N-myristoyltransferase by approximately 50{\%} at concentrations of 50-100 μM. The compounds in series 4 and 5 were well tolerated in a short-term toxicity study in mice.",
keywords = "3,5-Bis(arylidene)-4-piperidones, Cytostatic activity, Human N-myristoyltransferase, Molecular modeling, Murine toxicity",
author = "Amitabh Jha and Chandrani Mukherjee and Prasad, {Ashok K.} and Parmar, {Virinder S.} and Clercq, {Erik De} and Jan Balzarini and Stables, {James P.} and Manavathu, {Elias Kurian} and Anuraag Shrivastav and Sharma, {Rajendra K.} and Nienaber, {Kurt H.} and Zello, {Gordon A.} and Dimmock, {Jonathan R.}",
year = "2007",
month = "9",
day = "1",
doi = "10.1016/j.bmc.2007.05.065",
language = "English (US)",
volume = "15",
pages = "5854--5865",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "17",

}

TY - JOUR

T1 - E,E,E-1-(4-Arylamino-4-oxo-2-butenoyl)-3,5-bis(arylidene)-4-piperidones

T2 - A topographical study of some novel potent cytotoxins

AU - Jha, Amitabh

AU - Mukherjee, Chandrani

AU - Prasad, Ashok K.

AU - Parmar, Virinder S.

AU - Clercq, Erik De

AU - Balzarini, Jan

AU - Stables, James P.

AU - Manavathu, Elias Kurian

AU - Shrivastav, Anuraag

AU - Sharma, Rajendra K.

AU - Nienaber, Kurt H.

AU - Zello, Gordon A.

AU - Dimmock, Jonathan R.

PY - 2007/9/1

Y1 - 2007/9/1

N2 - A series of E,E,E-3,5-bis(arylidene)-1-(4-arylamino-4-oxo-2-butenoyl)-4-piperidones 4 (phenylidene) and 5 (4-nitrophenylidene) were prepared in order to explore the structural features of the N-acyl group which affects the cytotoxic potency. Evaluation toward human Molt 4/C8 and CEM T-lymphocytes revealed that many of the IC50 figures were submicromolar and lower than melphalan. Marked inhibitory potencies toward murine leukemia L1210 cells were also noted. When evaluated against a panel of human tumor cell lines, three representative compounds in series 4 displayed selective toxicity to leukemia and colon cancer cell lines and were significantly more potent than the reference drug melphalan. Molecular modeling of representative compounds in both series 4 and the analogs, in which the configuration of the olefinic double bond was changed from E to Z (series 3), revealed that the torsion angles of the arylidene aryl rings and locations of the terminal arylaminocarbonyl groups may have contributed to the greater cytotoxic properties displayed in 3. Compounds 4c (3,4-dichlorophenylamino), d (4-methylphenylamino) and 5c (3,4-dichlorophenylamino), d (4-methylphenylamino) inhibited the activity of human N-myristoyltransferase by approximately 50% at concentrations of 50-100 μM. The compounds in series 4 and 5 were well tolerated in a short-term toxicity study in mice.

AB - A series of E,E,E-3,5-bis(arylidene)-1-(4-arylamino-4-oxo-2-butenoyl)-4-piperidones 4 (phenylidene) and 5 (4-nitrophenylidene) were prepared in order to explore the structural features of the N-acyl group which affects the cytotoxic potency. Evaluation toward human Molt 4/C8 and CEM T-lymphocytes revealed that many of the IC50 figures were submicromolar and lower than melphalan. Marked inhibitory potencies toward murine leukemia L1210 cells were also noted. When evaluated against a panel of human tumor cell lines, three representative compounds in series 4 displayed selective toxicity to leukemia and colon cancer cell lines and were significantly more potent than the reference drug melphalan. Molecular modeling of representative compounds in both series 4 and the analogs, in which the configuration of the olefinic double bond was changed from E to Z (series 3), revealed that the torsion angles of the arylidene aryl rings and locations of the terminal arylaminocarbonyl groups may have contributed to the greater cytotoxic properties displayed in 3. Compounds 4c (3,4-dichlorophenylamino), d (4-methylphenylamino) and 5c (3,4-dichlorophenylamino), d (4-methylphenylamino) inhibited the activity of human N-myristoyltransferase by approximately 50% at concentrations of 50-100 μM. The compounds in series 4 and 5 were well tolerated in a short-term toxicity study in mice.

KW - 3,5-Bis(arylidene)-4-piperidones

KW - Cytostatic activity

KW - Human N-myristoyltransferase

KW - Molecular modeling

KW - Murine toxicity

UR - http://www.scopus.com/inward/record.url?scp=34447329017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447329017&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2007.05.065

DO - 10.1016/j.bmc.2007.05.065

M3 - Article

VL - 15

SP - 5854

EP - 5865

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 17

ER -